SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 1, 2004
Interleukin Genetics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-23413 |
|
94-3123681 |
|
(State or other |
|
(Commission |
|
(IRS Employer |
135 Beaver Street, Waltham, MA 02452
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (781) 398-0700
Item 5. Other Events.
On July 1, 2004, Interleukin Genetics, Inc. publicly disseminated a press release announcing that it had signed a Research Agreement with Access Business Group LLC, a subsidiary of Alticor Inc., to conduct research into the development of a test to identify individuals with specific genetic variations that affect how people gain and maintain weight.
The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
99.1 Press Release dated July 1, 2004
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Interleukin Genetics, Inc. |
|
|
|
|
(Registrant) |
||
|
|
|
||
|
|
|
||
|
Date: July 2, 2004 |
/s/ Fenel M. Eloi |
|
|
|
|
Fenel M. Eloi |
||
|
|
Chief Operating Officer, |
||
|
|
Chief Financial Officer, |
||
|
|
Treasurer and Secretary |
||
3